Little biotech developing Genentech castoff drug hits hurdle in glioblastoma platform trial

Amber Tong

When the Global Coalition for Adaptive Research brought the PI3K inhibitor paxalisib into its platform trial for glioblastoma in early 2021, the drug’s developer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Little biotech developing Genentech castoff drug hits hurdle in glioblastoma platform trial

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

Lit­tle biotech de­vel­op­ing Genen­tech castoff drug hits hur­dle in glioblas­toma plat­form tri­al

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Little biotech developing Genentech castoff drug hits hurdle in glioblastoma platform trial

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data